ABSTRACT
【Objective】 To study the effects of different activators and doses on the concentration of growth factor in platelet rich plasma(PRP). 【Methods】 15 healthy volunteers, recruited to prepare PRP by COM.TEC blood cell separator, were divided into 5 groups: PRP group with no activator, Calcium gluconate PRP group, Thrombin 100U/ mL-PRP group, Thrombin 50U/ mL-PRP group, and Thrombin 100U/ml-calcium gluconate -PRP group. The white blood cell count and platelet count in PRP and whole blood were detected. The concentrations of PDGF-AA, TGF-βand VEGF in PRP inactive group and 4 different activators 1 hour after activation were determined by ELISA. 【Results】 The mean concentration of platelets in PRP was 1 462.86×109/L, which was 5.77 times that in the whole blood. The mean concentrations (pg/mL) of PDGF-AA(174 348.00±132 872.39 vs 217 909.67±182 517.96 vs 221 020.38±153 321.51 vs 208 550.35±177 100.47), TGF-β(12 573.14±3 173.20 vs 14 678.45±5 880.96 vs 14 694.39±5 083.90 vs 12 675.65±4 981.83) and VEGF (653.45±489.82 vs 671.61±506.68 vs 690.05±416.13 vs 678.93±501.07) in 4 different activator groups were significantly higher than those in inactivated group (P<0.05). There was no significant difference in the concentrations of PDGF-AA, TGF-βand VEGF among different activators. Platelet concentration(1 462.86±628.41×109/L) in PRP had a strong positive correlation with PDGF concentration (221 020.38±153 321.51 pg/mL)in thrombin 50 U/ mL-PRP group (P<0.05) and TGF-βconcentration(pg/mL) (12 573.14±3 173.20 vs 14 678.45±5 880.96 vs 14 694.39±5 083.90 vs 12 675.65±4 981.83, respectively) in four different activator groups (P<0.05), but had no correlation with VEGF in each group. 【Conclusion】 PRP was prepared by blood cell separator with high purity. There was no difference in the concentrations of PDGF-AA, TGF-βand VEGF among different activators and different thrombin doses. The correlation between platelet concentration and growth factor concentration in PRP was related to the type of activator and growth factor.
ABSTRACT
Allogeneic stem cell transplantation is the only treatment which may cure multiple myeloma (MM).The high transplantation related mortality (TRM) limits the wide clinical application of myeloablative allogeneic stem cell transplantation.Non-myeloablative allogeneic stem cell transplantation can reduce the TRM,but the risk of relapse and progress of the disease may get increased. Autononmyeloablative allogeneic stem cell tandem transplantation can reduce both the TRM and the relapse and progress of the disease. At present,there exist many new methods which may improve the effect of allogeneic stem cell transplantation for MM in clinical.